Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by 9c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.05), $0.09 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $50.03 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Schwab's May activity shows margin loans nearly double